AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7905919 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam (.1 mg/kg)
Number of subjects: 60
Study 2567114 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (200, 400, 800, 1,600 mg)
Number of subjects: 2
Study 2567114 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100, 200, 300, 400 mg)
Number of subjects: 2
Study 2567114 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (100, 200, 400, 800 mg)
Number of subjects: 2
Study 2567114 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50, 100 mg)
Number of subjects: 2
Study 5312322 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (5 mg/kg body-weight daily)
Number of subjects: 0
Study 5312322 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (simultaneously with BCG vaccination)
Number of subjects: 0
Study 5312322 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 0
Study 31387081 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced preschool day (25% sitting)
Number of subjects: 29
Study 31387081 — intervention group
Group type: COMPARATOR
Intervention: Typical preschool day (50% sitting)
Number of subjects: 29
Study 28467383 — intervention group
Group type: EXPERIMENTAL
Intervention: Total urinary polyphenol excretion (TPE) measured by the Folin‐Ciocalteu method
Number of subjects: 573
Study 25244700 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloons (DEB)
Number of subjects: 310
Study 25244700 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 310
Study 23715820 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (DI)
Number of subjects: 30
Study 23715820 — intervention group
Group type: COMPARATOR
Intervention: Exercise (EX)
Number of subjects: 30
Study 23715820 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and Diet (EXD)
Number of subjects: 30
Study 21324213 — intervention group
Group type: EXPERIMENTAL
Intervention: KAAA (Keto analogues and amino acids)
Number of subjects: 13
Study 21324213 — intervention group
Group type: COMPARATOR
Intervention: Lactose (Control group; LEx)
Number of subjects: 13
Study 21324213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 13
Study 21324213 — intervention group
Group type: EXPERIMENTAL
Intervention: KAAA (KEx)
Number of subjects: 13
Study 18487854 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet release before wound closure
Number of subjects: 20
Study 18487854 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet release after wound closure
Number of subjects: 20
Study 16563521 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 to 20 mg/d)
Number of subjects: 788
Study 16563521 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine-fluoxetine combination (6 and 25, 6 and 50, or 12 and 50 mg/d)
Number of subjects: 788
Study 16563521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 788
Study 12878921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 microg/kg twice daily for 8 weeks)
Number of subjects: 40
Study 10719404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pecan treatment group (68 g pecans per day for 8 weeks)
Number of subjects: 19
Study 10719404 — intervention group
Group type: COMPARATOR
Intervention: Control group (avoided nuts)
Number of subjects: 19
Study 10719404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pecan treatment group
Number of subjects: 19
Study 10719404 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 9013266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg
Number of subjects: 129
Study 9013266 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 129
Study 1358119 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-3PPP (preclamol) administered intramuscularly at doses of 30-40 mg
Number of subjects: 4
Study 1358119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 6608327 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intercostal nerve block for five days
Number of subjects: 20
Study 6608327 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral thoracotomy
Number of subjects: 20
Study 6608327 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 20
Study 31698420 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic and transcriptomic association of 16 novel susceptibility loci for VTE
Number of subjects: 0
Study 31698420 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization
Number of subjects: 0
Study 28575490 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided (USG) venipuncture
Number of subjects: 320
Study 28575490 — intervention group
Group type: COMPARATOR
Intervention: Conventional venipuncture
Number of subjects: 320
Study 24571169 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics, taken twice a day for 2 weeks before surgery
Number of subjects: 30
Study 24571169 — intervention group
Group type: COMPARATOR
Intervention: Placebo, taken twice a day for 2 weeks before surgery
Number of subjects: 30
Study 24958486 — intervention group
Group type: EXPERIMENTAL
Intervention: TURis system
Number of subjects: 136
Study 24958486 — intervention group
Group type: COMPARATOR
Intervention: Conventional monopolar technique
Number of subjects: 136
Study 22753904 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated cetuximab (500 mg/m2 per week)
Number of subjects: 157
Study 22753904 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cetuximab (400 mg/m2 initial dose, then 250 mg/m2 per week)
Number of subjects: 157
Study 22753904 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated cetuximab (500 mg/m2 per week) in KRAS wild-type tumors
Number of subjects: 157
Study 22753904 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cetuximab (400 mg/m2 initial dose, then 250 mg/m2 per week) in KRAS wild-type tumors
Number of subjects: 157
Study 20444847 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy with carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 15-3 monitoring
Number of subjects: 63
Study 17013650 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 181
Study 17013650 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine-sulfalene-pyrimethamine (ASP)
Number of subjects: 181
Study 16150198 — intervention group
Group type: EXPERIMENTAL
Intervention: Gankangyin (GKY) for 3 months
Number of subjects: 96
Study 16150198 — intervention group
Group type: COMPARATOR
Intervention: Silymarin for 3 months
Number of subjects: 96
Study 12114886 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg/day
Number of subjects: 553
Study 12114886 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg/day
Number of subjects: 553
Study 12114886 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg/day
Number of subjects: 553
Study 12114886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study 12114886 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (all doses) in severe cases
Number of subjects: 553
Study 11035129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (300 mg b.d.)
Number of subjects: 812
Study 11035129 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg t.d.s.)
Number of subjects: 812
Study 11035129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 812
Study 11035129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid and Indomethacin
Number of subjects: 812
Study 11035129 — intervention group
Group type: COMPARATOR
Intervention: Tiaprofenic acid and Placebo
Number of subjects: 812
Study 8633584 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 1 (B 150 mg q.i.d., OT 500 mg q.i.d., M 400 mg t.i.d. for 10 days and R 300 mg b.i.d. for 4 wk)
Number of subjects: 180
Study 8633584 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 2 (same as regimen 1 except ranitidine)
Number of subjects: 180
Study 8633584 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 3 (same as regimen 1 except metronidazole)
Number of subjects: 180
Study 8633584 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 4 (same as regimen 1 except metronidazole and ranitidine)
Number of subjects: 180
Study 8633584 — intervention group
Group type: COMPARATOR
Intervention: Regimens 1+2 (with metronidazole)
Number of subjects: 180
Study 8633584 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens 1+3 (with ranitidine)
Number of subjects: 180
Study 8633584 — intervention group
Group type: COMPARATOR
Intervention: Regimens 2+4 (without ranitidine)
Number of subjects: 180
Study 8633584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (during therapy)
Number of subjects: 180
Study 1572471 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH)
Number of subjects: 28
Study 1572471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3985430 — intervention group
Group type: COMPARATOR
Intervention: Enflurane at an inspired concentration of 2.5% during hypothermia (28 degrees C)
Number of subjects: 0
Study 3985430 — intervention group
Group type: COMPARATOR
Intervention: Enflurane during hypothermic CPB
Number of subjects: 0
Study 30979409 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Psychology-Motivational Interviewing (PP-MI)
Number of subjects: 47
Study 30979409 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched, MI-based health education control
Number of subjects: 47
Study 29754666 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol hydrochloride
Number of subjects: 620
Study 29754666 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol succinate
Number of subjects: 620
Study 26176643 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150-300 mg)/Amlodipine (5 mg) (ALI/AML group, n=53)
Number of subjects: 105
Study 26176643 — intervention group
Group type: COMPARATOR
Intervention: High-dose Amlodipine (10 mg) (h-dAML group, n=52)
Number of subjects: 105
Study 26176643 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ALI/AML and h-dAML groups
Number of subjects: 105
Study 24762158 — intervention group
Group type: EXPERIMENTAL
Intervention: Biceps repair
Number of subjects: 37
Study 24762158 — intervention group
Group type: EXPERIMENTAL
Intervention: Biceps tenodesis
Number of subjects: 37
Study 22429255 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 35
Study 22429255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 20226329 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin regimen
Number of subjects: 4372
Study 20226329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4372
Study 17470315 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (0.25 mg, 1 mg, or 4 mg b.i.d.)
Number of subjects: 150
Study 17470315 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 150
Study 15933930 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal esophagoscopy
Number of subjects: 90
Study 15933930 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral esophagoscopy
Number of subjects: 90
Study 15933930 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopy (sedated)
Number of subjects: 90
Study 15933930 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mm video esophagoscope
Number of subjects: 90
Study 15933930 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedure anxiety
Number of subjects: 90
Study 15933930 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 90
Study 12364985 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP laser ablation after anti-reflux surgery
Number of subjects: 9
Study 12364985 — intervention group
Group type: COMPARATOR
Intervention: Fundoplication alone
Number of subjects: 9
Study 10486789 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Number of subjects: 148
Study 10486789 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Number of subjects: 148
Study 10486789 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT/ERT
Number of subjects: 148
Study 10486789 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated women)
Number of subjects: 148
Study 9138995 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps delivery
Number of subjects: 170
Study 9138995 — intervention group
Group type: COMPARATOR
Intervention: Normal vaginal delivery
Number of subjects: 170
Study 30094885 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal washing before intravaginal dinoprostone insertion (10 mg dinoprostone via Propess system)
Number of subjects: 191
Study 30094885 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaginal washing before intravaginal dinoprostone insertion)
Number of subjects: 191
Study 26990824 — intervention group
Group type: EXPERIMENTAL
Intervention: Early integrated ART initiation during TB treatment
Number of subjects: 642
Study 26990824 — intervention group
Group type: EXPERIMENTAL
Intervention: Late integrated ART initiation during TB treatment
Number of subjects: 642
Study 26990824 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed ART initiation after TB treatment completion
Number of subjects: 642
Study 26990824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 642
Study 24902992 — intervention group
Group type: EXPERIMENTAL
Intervention: Football Training (FTG)
Number of subjects: 26
Study 24902992 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (STG)
Number of subjects: 26
Study 22387008 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% discount on healthy foods
Number of subjects: 150
Study 22387008 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% discount on healthy foods
Number of subjects: 150
Study 22387008 — intervention group
Group type: COMPARATOR
Intervention: No discount on healthy foods
Number of subjects: 150
Study 22387008 — intervention group
Group type: COMPARATOR
Intervention: Price increases on unhealthy foods (5%, 10%, 25%)
Number of subjects: 150
Study 20048658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative thoracic epidural bupivacaine perfusion (0.5% at 3 mL/hr) with preoperative intrathecal morphine (0.5 mg) and fentanyl (15 microg)
Number of subjects: 44
Study 20048658 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham epidural) with the same intrathecal narcotics
Number of subjects: 44
Study 20048658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative thoracic epidural bupivacaine
Number of subjects: 44
Study 17968337 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study 17968337 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 17968337 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced analytical techniques
Number of subjects: 0
Study 15864023 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study 12472591 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lenograstim during the first 12 weeks of standard immunosuppressive therapy
Number of subjects: 102
Study 12472591 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppressive therapy (control group)
Number of subjects: 102
Study 9619322 — intervention group
Group type: EXPERIMENTAL
Intervention: E-5510
Number of subjects: 7
Study 9619322 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 7
Study 8749707 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Number of subjects: 36
Study 8749707 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulins (IVIg)
Number of subjects: 36
Study 8749707 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange (PE) and Intravenous immune globulins (IVIg)
Number of subjects: 36
Study 8749707 — intervention group
Group type: COMPARATOR
Intervention: Single therapy (either PE or IVIg)
Number of subjects: 36
Study 8749707 — intervention group
Group type: COMPARATOR
Intervention: Second cycle of therapy (either PE or IVIg)
Number of subjects: 36
Study 2494973 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 97
Study 2494973 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 97
Study 324571 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative dose of cephazolin
Number of subjects: 201
Study 324571 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative dose of cephazolin plus a five-day course postoperatively
Number of subjects: 201
Study 324571 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cephazolin)
Number of subjects: 201
Study 29205165 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine ciprofloxacin prophylaxis (Group 1, n=156)
Number of subjects: 300
Study 29205165 — intervention group
Group type: COMPARATOR
Intervention: Targeted prophylactic antibiotic regime (Group 2, n=144)
Number of subjects: 300
Study 29205165 — intervention group
Group type: COMPARATOR
Intervention: Targeted prophylactic antibiotic regime (Group 2)
Number of subjects: 300
Study 25726497 — intervention group
Group type: EXPERIMENTAL
Intervention: Active DBS treatment
Number of subjects: 30
Study 25726497 — intervention group
Group type: COMPARATOR
Intervention: Sham DBS treatment
Number of subjects: 30
Study 24460318 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-Based Intervention (EBI)
Number of subjects: 232
Study 21504934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided TAP blocks
Number of subjects: 93
Study 21504934 — intervention group
Group type: COMPARATOR
Intervention: Control (no TAP blocks)
Number of subjects: 93
Study 19804515 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (12 mg)
Number of subjects: 74
Study 19804515 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (10 mg)
Number of subjects: 74
Study 19804515 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 74
Study 19804515 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 74
Study 17057049 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-managed diabetes care program
Number of subjects: 149
Study 17057049 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes care (Control)
Number of subjects: 149
Study 12635025 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan alone or combined with hydrochlorothiazide
Number of subjects: 11447
Study 11783325 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine (TCM-WM) treatment including prednisone, Cytoxan (CTX), and Chinese medicinal herbs according to Syndrome-type.
Number of subjects: 82
Study 11783325 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with Western medicine (WM) alone.
Number of subjects: 82
Study 11783325 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine (TCM-WM) treatment.
Number of subjects: 82
Study 11783325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups.
Number of subjects: 82
Study 9166162 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 24
Study 9166162 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone
Number of subjects: 24
Study 9166162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1589731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 82
Study 3899240 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMW heparin) 1850 APTT units (7500 antifactor Xa units)
Number of subjects: 395
Study 3899240 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated (UF) calcium heparin 10000 APTT units
Number of subjects: 395
Study 3899240 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of LMW heparin every day
Number of subjects: 395
Study 30382820 — intervention group
Group type: EXPERIMENTAL
Intervention: Women referred with obstructed labor
Number of subjects: 84924
Study 30382820 — intervention group
Group type: EXPERIMENTAL
Intervention: Grand multiparity (> 5 live births)
Number of subjects: 84924
Study 30382820 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior cesarean
Number of subjects: 84924
Study 30382820 — intervention group
Group type: EXPERIMENTAL
Intervention: Resides outside hospital region
Number of subjects: 84924
Study 30382820 — intervention group
Group type: EXPERIMENTAL
Intervention: No prenatal care visits
Number of subjects: 84924
Study 30382820 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight of > 3600 g
Number of subjects: 84924
Study 27245485 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of elastic compression stockings (ECS) for 24 months after diagnosis of deep venous thrombosis.
Number of subjects: 518
Study 27245485 — intervention group
Group type: COMPARATOR
Intervention: Stopping elastic compression stockings (ECS) after 12 months.
Number of subjects: 518
Study 27245485 — intervention group
Group type: COMPARATOR
Intervention: Continuation of ECS for 24 months versus stopping ECS after 12 months.
Number of subjects: 518
Study 27245485 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (VEINES-QOL/Sym) assessment.
Number of subjects: 518
Study 24068750 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive-behavioral psychotherapy (14 one-hour weekly sessions)
Number of subjects: 25
Study 24068750 — intervention group
Group type: COMPARATOR
Intervention: Conventional cognitive-behavioral psychotherapy (14 one-hour weekly sessions)
Number of subjects: 25
Study 22673017 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH(4)) 10 mg·kg(‐1) body weight
Number of subjects: 8
Study 22673017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 20064056 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐based personal health site (Mellen Center Care On‐line) for self-management of multiple sclerosis symptoms
Number of subjects: 2041
Study 20064056 — intervention group
Group type: COMPARATOR
Intervention: Patient nonresponders (PNR)
Number of subjects: 2041